Результаты поиска

Статинское воздействие после многократного диагностирования миеломы и риск полной смертности, венозного тромбоэмболизма, патологических переломов и острых повреждений почек: ретроспективное когортное исследование.

Множественная миелома (ММ) сопряжена со значительным риском венозного тромбоэмболизма (VTE), патологических переломов, острых повреждений почек (AKI) и смерти. Статины обладают антивоспалительными, иммунодуляционными и антитромботическими свойствами, которые могут уменьшить эти осложнения, однако их связи с рядом ключевых результатов MM не оценивались одновременно в одной реальной группе. ЦЕЛИ: Оценить связь между воздействием последиагностической статистики и 5-year Смертельная смертность, VTE, патологические переломы и AKI в MM. МЕТОДЫ: Мы провели ретроспективное когортное исследование в сет

Совпадение в полном тексте источника
… The statin-exposed cohort included patients with any statin exposure, identified using RxNorm codes for rosuvastatin, simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, or pitavastatin, where the first qualifying statin record occurred on or after the first MM diagnosis. …

Topical Simvastatin Improves Lesions of Diffuse Normolipemic Plane Xanthoma by Inhibiting Foam Cell Pyroptosis.

Xanthoma pathogenesis is speculated to be associated with oxidized low-density lipoprotein (ox-LDL) deposition, although this remains unclear. Most patients with diffuse plane xanthomas present elevated blood lipid levels, and they benefit from treatment with oral lipid-lowering agents. However, there is no available treatment for diffuse normolipemic plane xanthoma (DNPX). In this study, for the first time, we used a topical simvastatin ointment to treat DNPX in three pediatric patients and observed favorable results. Immunofluorescence staining showed that the pyroptotic pathway was signific

Совпадение в полном тексте источника
… No significant differences were observed among the effects of simvastatin, pravastatin, and lovastatin on foam cell pyroptosis ( Supplementary Figures 5A–G ). Statins inhibit HMGCR, a rate-limiting enzyme in cholesterol synthesis ( 27 ). …

Chronic obstructive pulmonary disease with short-acting inhaled pharmacotherapy increases the risk of prostate cancer: A two-stage database approach.

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) are at a higher risk of many types of cancer. However, specific investigation of the risk of prostate cancer and the influence of COPD pharmacotherapy in patients with COPD is lacking. This study investigated the risk and influence of COPD pharmacotherapy on risk of prostate cancer in patients with COPD. METHODS: This retrospective cohort study used data from Taiwan's Longitudinal Health Insurance Database 2005 (LHID2005). The study cohort comprised COPD patients who received treatment between 2004 and 2008, and who were i

Совпадение в полном тексте источника
… In addition to inhaled medicine, other medication such as aspirin, oral form of steroid, nonsteroidal anti-inflammatory drugs (NSAIDs), and the statins (included simvastatin (ATC code C10AA01), lovastatin (ATC code C10AA02), pravastatin (ATC code C10AA03), fluvastatin (ATC code C10AA04), and atorvastatin …

JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies.

JAK/STAT signaling pathway is one of the important regulatory signaling cascades for the myriad of cellular processes initiated by various types of ligands such as growth factors, hormones, and cytokines. The physiological processes regulated by JAK/STAT signaling are immune regulation, cell proliferation, cell survival, apoptosis and hematopoiesis of myeloid and non-myeloid cells. Dysregulation of JAK/STAT signaling is reported in various immunological disorders, hematological and other solid malignancies through various oncogenic activation mutations in receptors, downstream mediators, and a

Совпадение в полном тексте источника
… Inhibitor | Target | Effect | Indication (clinical trial phase) Non-peptide small molecules Pravastatin | STAT1 | downregulates IFN-γ levels | gastroesophageal cancer (phase IV) Non-peptide small molecules pravastatin | STAT1 | Phosphorylation inhibition of STAT1, decrease in IFNγ levels | gastroesophageal …

Drug repurposing approach to fight COVID-19.

Currently, there are no treatment options available for the deadly contagious disease, coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new uses for approved or investigational drugs and it is considered as a very effective strategy for drug discovery as it involves less time and cost to find a therapeutic agent in comparison to the de novo drug discovery process. The present review will focus on the repurposing efficacy of the currently used drugs against COVID-19 and their mechanisms of action, pharmacokinetics, dosing, safety, and their future perspective. R

Совпадение в полном тексте источника
… Fungus derived statins (lovastatin, pravastatin and simvastatin) have elimination half-lives of 1–3 h and other synthetic compounds have elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin. Bioavailability of statins varies from 5–80% and 6–30% of the absorbed statins. … All statins are extensively bound to plasma proteins (> 90%) with the exception to pravastatin which is only 50% bound to plasma proteins [ 158 ]. Myopathy and rhabdomyolysis are the most frequent adverse effect of statins. …

Acute myeloid leukemia: focus on novel therapeutic strategies.

Acute myeloid leukemia (AML) is a heterogeneous disease with variable clinical outcomes. Cytogenetic analysis reveals which patients may have favorable risk disease, but 5-year survival in this category is only approximately 60%, with intermediate and poor risk groups faring far worse. Advances in our understanding of the biology of leukemia pathogenesis and prognosis have not been matched with clinical improvements. Unsatisfactory outcomes persist for the majority of patients with AML, particularly the elderly. Novel agents and treatment approaches are needed in the induction, post-remission

Совпадение в полном тексте источника
… All-trans retinoic acid, bexarotene Antibody-drug conjugate | Gemtuzumab Alkylating agents | Bendamustine Farnesyltransferase inhibitor | Tipifarnib Hedgehog pathway inhibitor | PF-0449 PI3K/AKT pathway inhibitor | ON 01910.Na HSP-90 inhibitor | Elesclomol sodium Angiokinase inhibitor | BIBF 1120 Statins | Pravastatin …

Chronic pruritus: a narrative review.

Chronic pruritus encompasses a manifestation of several cutaneous, allergic, infectious, neurological, psychological, and systemic conditions, whose etiological investigation and therapeutic strategy can be challenging. This comprehensive review aims to enhance the understanding of pruritus by highlighting important elements in its pathogenesis, including keratinocytes, Merkel cells and mast cells, nerve fibers, histaminergic and nonhistaminergic pathways, and the interaction of itch signals with the central nervous system. Diagnostic evaluation of chronic pruritus may require a meticulous app

Rhabdomyolysis secondary to COVID-19 infection and vaccination: a review of literature.

Rhabdomyolysis (RML), characterized by the breakdown of skeletal muscle fibers and the release of muscle contents into the bloodstream, has emerged as a notable complication associated with Coronavirus disease 2019 (COVID-19) infection and vaccination. Studies have reported an increased incidence of RML in individuals with severe COVID-19 infection. However, the exact mechanisms remain unclear and are believed to involve the host's immune response to the virus. Furthermore, RML has been documented as a rare adverse event following COVID-19 vaccination, particularly with mRNA vaccines. Proposed

Совпадение в полном тексте источника
… The patient was on Lisinoprol pravastatin 40 mg with positive past myotoxic DH. Lab results revealed a peak CK of 7,854 creatinine of 5.3. …

HIV infection in the elderly.

In the US, an estimated 1 million people are infected with HIV, although one-third of this population are unaware of their diagnosis. While HIV infection is commonly thought to affect younger adults, there are an increasing number of patients over 50 years of age living with the condition. UNAIDS and WHO estimate that of the 40 million people living with HIV/AIDS in the world, approximately 2.8 million are 50 years and older. With the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s, survival following HIV diagnosis has risen dramatically and HIV infection has evol

Совпадение в полном тексте источника
… Alternative statins with limited to no clinically significant drug interactions with PIs include Fluvastatin, Pravastatin, and low-dose Atorvastatin. Another potent statin option available for the management of hyperlipidemia in HIV-negative patients is Rosuvastatin. …

Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals.

In cancer, a patient is considered a survivor from the time of initial diagnosis until the end of life. With improvements in early diagnosis and treatment, the number of cancer survivors (CS) has grown considerably and includes: (1) Patients cured and free from cancer who may be at risk of late-onset cancer therapy-related cardiovascular toxicity (CTR-CVT); (2) Patients with long-term control of not-curable cancers in whom CTR-CVT may need to be addressed. This paper highlights the importance of the cancer care continuum, of a patient-centered approach and of a prevention-oriented policy. The

Совпадение в полном тексте источника
… Pravastatin reduces radiation-induced damage in normal tissues. Exp Ther Med. (2017) 13:1765–72. 10.3892/etm.2017.4192 114. van der Veen SJ, Ghobadi G, de Boer RA, Faber H, Cannon MV, Nagle PW, et al. ACE Inhibition attenuates radiation-induced cardiopulmonary damage. …

Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization.

The use of nanotechnology in medicine has the potential to have a major impact on human health for the prevention, diagnosis, and treatment of diseases. One particular aspect of the nanomedicine field which has received a great deal of attention is the design and development of nanoparticulate nanomedicines (NNMs) for drug delivery (i.e., drug-containing nanoparticles). NNMs are intended to deliver drugs via various mechanisms: solubilization, passive targeting, active targeting, and triggered release. The NNM approach aims to increase therapeutic efficacy, decrease the therapeutically effecti

Совпадение в полном тексте источника
… Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation . J. Control Release . 148 , 303 – 310 . 10.1016/j.jconrel.2010.09.011 20869410 Crielaard B. J. Lammers T. Schiffelers R. M. Storm G. ( 2012 ). …

Resveratrol and Cardiovascular Diseases.

The increased incidence of cardiovascular diseases (CVDs) has stimulated research for substances that could improve cardiovascular health. Among them, resveratrol (RES), a polyphenolic compound notably present in grapes and red wine, has been involved in the "French paradox". RES is known for its antioxidant and anti-inflammatory properties and for its ability to upregulate endothelial NO synthase (eNOS). RES was able to scavenge (•)OH/O₂(•-) and peroxyl radicals, which can limit the lipid peroxidation processes. Moreover, in bovine aortic endothelial cells (BAEC) under glucose-induced oxidati

Совпадение в полном тексте источника
… As reported by Cho et al. [ 29 ], RES could also potentiate the hypocholesterolemiant action of pravastatin, by down-regulating the 3-hydroxy-3-methyl-glutaryl-CoAreductase (HMG-CoA reductase), an enzyme that intervenes in the first steps of cholesterol biosynthesis. …

Novel Therapeutics for Anthracycline Induced Cardiotoxicity.

Anthracyclines remain an essential component of the treatment of many hematologic and solid organ malignancies, but has important implications on cardiovascular disease. Anthracycline induced cardiotoxicity (AIC) ranges from asymptomatic LV dysfunction to highly morbid end- stage heart failure. As cancer survivorship improves, the detection and treatment of AIC becomes more crucial to improve patient outcomes. Current treatment modalities for AIC have been largely extrapolated from treatment of conventional heart failure, but developing effective therapies specific to AIC is an area of growing

Совпадение в полном тексте источника
… There is an ongoing ATACAR (AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment) study evaluating pravastatin and spironolactone in addition to maximally tolerated carvedilol and lisinopril for prevention of AIC ( 28 ). …

Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management.

The first part of this review highlighted the evolving landscape of atherosclerosis, noting emerging cardiometabolic risk factors, the growing impact of exposomes, and social determinants of health. The prominent role of atherosclerosis in the bidirectional relationship between cardiovascular disease and cancer was also discussed. In this second part, we examine the complex interplay between multimorbid cardio-oncologic patients, cardiometabolic risk factors, and the harmful environments that lend a "syndemic" nature to these chronic diseases. We summarize management strategies targeting disor

Совпадение в полном тексте источника
… Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators C-reactive protein levels and outcomes after statin therapy N. Engl. J. Med. 2005 352 20 28 10.1056/NEJMoa042378 15635109 139. Morrow D.A. de Lemos J.A. …

Aminopeptidase N: a multifunctional and promising target in medicinal chemistry.

Aminopeptidase N (APN) is a zinc metalloproteinase present in almost all types of organisms and has various functions. Many of them are unrelated to its catalytic activity, which is why APN is sometimes classified as a moonlighting enzyme. APN is involved in carcinogenesis and angiogenesis. It also works as an entrance receptor for some coronaviruses and acts as a mediator during skin inflammation. Additionally, APN removes and helps to recycle regulatory proteins including neuropeptides, which is why its inhibitors hold therapeutic potential for a wide range of diseases, making the design and

Совпадение в полном тексте источника
… An alternative approach to potentiate APN inhibitory activity and overcome resistance in malignancies involves combination therapy, such as co-administration of tosedostat with statins—including simvastatin, fluvastatin, lovastatin, and pravastatin—for the treatment of aminopeptidase-resistant acute …

The updated landscape of tumor microenvironment and drug repurposing.

Accumulating evidence shows that cellular and acellular components in tumor microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and response to therapies. Cancer research and treatment have switched from a cancer-centric model to a TME-centric one, considering the increasing significance of TME in cancer biology. Nonetheless, the clinical efficacy of therapeutic strategies targeting TME, especially the specific cells or pathways of TME, remains unsatisfactory. Classifying the chemopathological characteristics of TME and crosstalk among one another can greatly b

Совпадение в полном тексте источника
… Statin Statin is an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase and is used to downregulate the lipid level, thereby playing a role in the prevention of cardiovascular diseases. 231 Statins can be classified as lipophilic (e.g., simvastatin and lovastatin) or hydrophilic (e.g., pravastatin …

Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside.

Despite impressive efforts invested in epigenetic research in the last 50 years, clinical applications are still lacking. Only a few university hospital centers currently use epigenetic biomarkers at the bedside. Moreover, the overall concept of precision medicine is not widely recognized in routine medical practice and the reductionist approach remains predominant in treating patients affected by major diseases such as cancer and cardiovascular diseases. By its' very nature, epigenetics is integrative of genetic networks. The study of epigenetic biomarkers has led to the identification of num

15th Конгресс Европейской ассоциации клинической фармакологии и терапии (ЕАКПТ)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Nano-formulations in disease therapy: designs, advances, challenges, and future directions.

Nano-formulations, as an innovative drug delivery system, offer distinct advantages in enhancing drug administration methods, improving bioavailability, promoting biodegradability, and enabling targeted delivery. By exploiting the unique size advantages of nano-formulations, therapeutic agents, including drugs, genes, and proteins, can be precisely reorganized at the microscale level. This modification not only facilitates the precise release of these agents but also significantly enhances their efficacy while minimizing adverse effects, thereby creating novel opportunities for treatment of a

Совпадение в полном тексте источника
… Furthermore, regarding cholesterol reduction, the curcumin nano-emulsion demonstrates substantial efficacy, even outperforming the standard drug pravastatin. …

An integrative review of nonobvious puzzles of cellular and molecular cardiooncology.

Oncologic patients are subjected to four major treatment types: surgery, radiotherapy, chemotherapy, and immunotherapy. All nonsurgical forms of cancer management are known to potentially violate the structural and functional integrity of the cardiovascular system. The prevalence and severity of cardiotoxicity and vascular abnormalities led to the emergence of a clinical subdiscipline, called cardiooncology. This relatively new, but rapidly expanding area of knowledge, primarily focuses on clinical observations linking the adverse effects of cancer therapy with deteriorated quality of life of